Solitary fibrous tumor (SFT) is a rare type of tumor. It generally
comprises a spectrum of benign mesenchymal tumors that have thick
collagen with hemangiopericytoma. Some of them can grow as malignant
tumors. SFTs were first described in 1931 and they were recognized by
several different names viz. pleural fibroma, benign mesothelioma,
sub-serosal fibroma, localized fibrous tumor, benign mesothelioma,
and solitary fibrous mesothelioma. Some of them are confused with
sinonasal hemangiopericytoma. Sinonasal hemangiopericytoma are
biologically, morphologically, and clinically very distinct from
SFTs. They are thought to be intrathoracic tumors, whereas 50% to 60%
of SFTs grow outside the thorax. Some of them develop in the central
nervous system (CNS). Research findings suggest that solitary fibrous
tumors usually affect adults (in mid-40s). They are observed equally
in men and women. Some of them are observed in adolescents and
children. The tumor site is broad and the tumor arises from visceral
location. More than 40% of SFTs are localized in the subcutaneous
tissues. Usually, dull pain and less growth are primary symptoms.
These tumors can also cause hypoglycemia, as some of them exhibit
production of insulin-like growth factors. About 15% to 20% of the
malignant tumors may infiltrate and metastasize to a different
location. Under microscope, these tumors show areas of collagen in
combination with hemangiopericytoma and hypocelluarity. Typical SFTs
show multinucleated giant cells with minimal cytoplasm and elongated
nuclei.
Report Overview @
https://www.transparencymarketresearch.com/solitary-fibrous-tumor-treatment-market.html
The global solitary fibrous tumor (SFT) treatment market is estimated
to expand rapidly in the next few years. Some of the driving factors
for the market are increase in the incidence of cancers, rise in
geriatric population worldwide, increase in awareness about cancer
and its recurrence, technological advancements, and adoption of newly
developed, minimally invasive techniques. Additionally, increase in
investments by pharmaceutical and biotechnology companies to develop
new molecular entities, advancements in chemotherapy, and better
reimbursement policies in developed countries are a few key factors
anticipated to augment the global solitary fibrous tumor (SFT)
treatment market during the forecast period. However, side-effects
caused by chemotherapy, increase in the cost of treatment, and lack
of skilled professionals hinder the global solitary fibrous tumor
(SFT) treatment market.
Based on type of treatment, the global solitary fibrous tumor (SFT)
treatment market can be segmented into surgery, radiation therapy,
and adjuvant chemotherapy. To date, research findings have not been
able to figure out which treatment is superior. For example, if SFTs
appear malignant, then adjuvant radiation therapy can be a good
option. While in some of them, complete excision is generally
preferred. After surgery or chemotherapy, long-term follow-up
treatment is recommended by doctors, as distant or local relapse is
possible, even in cases of benign tumors.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37022
Based on region, the global solitary fibrous tumor (SFT) treatment
market has been divided into North America, Europe, Asia Pacific,
Latin America, and Middle East & Africa. The market in North
America is estimated to expand rapidly in the next few years, due to
well-developed health care systems, proper reimbursement scenario,
and adoption of new and advanced techniques in the region. North
America is projected to be followed by Europe and Asia Pacific.
Presence of key players, increase in investments in R&D by
leading players, and alliance of key players with research institutes
are some of the factors driving the global solitary fibrous tumor
(SFT) treatment market.
Some of the key players operating in the global solitary fibrous
tumor (SFT) treatment market are Medtronic Plc, AstraZeneca plc, Sun
Pharmaceutical Industries Limited, Johnson & Johnson, Roche Ag,
and Pfizer.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=37022<ype=S
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment